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Introduction
Development of the hematopoietic system involves massive 
genome remodeling and the establishment of complex genetic 
networks. The transcription factor GATA-binding protein 2 
(GATA-2) establishes and maintains genetic networks governing 
hematopoietic stem and progenitor cell (HSPC) genesis and func-
tion (1–5) and is a major determinant of all blood cell lineages (6, 
7). Human GATA2 deficiency syndrome resulting from germline 
coding or enhancer (+9.5) mutations includes monocytopenia 
and mycobacterial infection syndrome (2, 8, 9); DC, monocyte, B, 
and NK lymphoid deficiency (10); Emberger syndrome (primary 
lymphedema with myelodysplastic syndromes [MDS]) (8, 10–12); 
and familial MDS/acute myeloid leukemia (AML) (11). These 
pathologies might extend beyond germline mutations, as a patient 
with a somatic GATA2 mutation had similar phenotypes (13). 
Though mechanisms underlying GATA-2 pathologies and their 
unpredictable onset are unresolved, a GATA-2 growth–promoting 
circuit in AML (14) with clinical relevance (15) has been described. 
The variable onset and multicomponent phenotypes character-
izing patients with GATA-2 deficiency syndrome (16–19) suggest 
that additional genetic and/or environment factors contribute to 
disease progression. Consistent with this inference, symptomatic 
patients often harbor additional mutations, e.g., in ASXL tran-
scriptional regulator 1 (ASXL1) (20), or cytogenetic abnormalities 
such as monosomy 7 (18).
Since murine Gata2 ablation is lethal at approximately E10.5 
(6), conditional (21, 22), heterozygous (23, 24), and enhancer- 
mutant mice (1, 2, 4, 5, 25) have been used to elucidate GATA-2 
regulation and function. Transcriptional control of GATA-2 
requires cell type–specific enhancers 9.5 kb downstream and 
77 kb upstream of the Gata2 start site (2, 5, 26). Whether these 
enhancers function and are essential in regenerative contexts 
is unknown. The +9.5 triggers hematopoietic stem cell (HSC) 
emergence from hemogenic endothelium and confers vascular 
integrity (1, 2) (Figure 1). While Gata2-mutant mice have not 
previously been found to have malignancies, GATA-2 mediates 
leukemogenesis in a Tet2 ablation and FLT3–internal tandem 
duplication–overexpression (FLT3-ITD–overexpression) AML 
mouse model (27). Thus, normal hematopoiesis requires strin-
gent GATA-2 regulation.
The +9.5 enhancer contains multiple transcription factor 
motifs, including an E-box–spacer–WGATAR and Ets motif (Fig-
ure 1). These include canonical binding motifs for the heptad 
of transcription factors and cofactors governing the generation 
of HSPCs (28), including stem cell leukemia/T cell acute lym-
phoblastic leukemia (SCL/TAL1) (E-box: CANNTG), GATA-2 
(WGATAR), and the Ets factors ETS-related gene (ERG) and Fli-1 
proto-oncogene (FLI1) (GGAW). The Gata2 +9.5 E-box, GATA, 
and downstream motifs (including the Ets motif) are essential for 
+9.5 site enhancer activity in reporter assays (29, 30), and human 
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able for embryogenesis, it enhanced Gata2 upregulation and 
HSPC regeneration in response to myeloablation. These results 
revealed the human genetics concept that disease mutation 
segregates regenerative versus developmental functions of 
an enhancer. Furthermore, our analyses with the unique in 
vivo models provided evidence for a paradigm of GATA-2– 
dependent pathogenesis.
Results
Multiple cis-elements within the Gata2 +9.5 enhancer collectively 
support HSPC genesis. The +9.5 deletion is embryonically lethal 
at approximately E14 (1, 2). It was unclear whether individual 
motifs within the +9.5 are essential or dispensable for enhancer 
activity. To test models to determine how distinct cis-elements 
contribute to +9.5 enhancer activity, we generated a mouse 
strain lacking the E-box and Ets, but retaining WGATAR 
[+9.5(E-box Ets)–/–] (Figure 2, A–C). We asked whether WGATAR 
confers any +9.5 activities in diverse cellular and development 
contexts, if it recapitulates the defects of +9.5–/– embryos, or if 
unique phenotypes emerge. By E13.5, +9.5(E-box Ets)–/– embryos 
showed a decrease of approximately 90% in fetal liver cellular-
ity and reduced fetal liver cellularity and size (Figure 2, D and 
E), resembling +9.5–/– embryos. We found that homozygous 
mutants had severe hemorrhages (100% penetrance) and vari-
able edema (Figure 2F) and died by E14.5 (Figure 2F and Table 
1). Gata2 mRNA levels in +9.5(E-box Ets)–/– fetal liver from live 
embryos were 23-fold lower than those in WT littermates (Fig-
ure 2G), also resembling +9.5–/– embryos.
patients with heterozygous disruptions of the +9.5 E-box or Ets 
motifs exhibit decreased GATA2 expression (2, 9). Deletion of 
the E-box–spacer–WGATAR (+9.5–/–) composite element reduced 
chromatin accessibility and abrogated occupancy of SCL/TAL1 
and its cofactor LIM domain–binding 1 (LDB1) in fetal liver cells 
(31), revealing +9.5 enhancer–dependent chromatin accessibility 
and regulatory complex assembly at the Gata2 locus.
Patients with GATA-2 deficiency syndrome with enhancer 
mutations can lack the E-box or harbor single-nucleotide Ets 
mutations (2, 9, 32) that disrupt the GGAW motif, which is 
essential for high-affinity DNA binding (33). Both the E-box 
and Ets motif mutations reduce GATA2 expression (2, 9). The 
Ets 1017+572C>T transition was detected in at least 6 families 
and is the most common noncoding GATA2 mutation described 
to date (9, 34–36). Neither of these mutations is predicted to 
introduce known transcription factor–binding motifs (37). Since 
E-box– and Ets motif–mutant patients share phenotypes, +9.5 
cis-elements might contribute equivalently to enhancer activ-
ity, including transcriptional complex assembly. Alternatively, 
different +9.5 cis-elements may exert qualitatively or quantita-
tively distinct functions, with essentially any corruption of +9.5 
enhancer activity being pathogenic.
Here, we generated mouse strains to test these models and 
found differential cis-element contributions to +9.5 enhancer 
function. Mutation of E-box and Ets motifs, with retention of 
WGATAR, abrogated HSC emergence and was embryonically 
lethal, resembling mice lacking the E-box–spacer–WGATAR 
composite element (2). Though the Ets motif was dispens-
Figure 1. The +9.5 enhancer WGATAR motif is insufficient for HSC genesis and function. (A) Mouse +9.5 mutations. Deletion of the E-box spacer GATA 
composite elements abrogates +9.5 function (2). The question marks denote uncertainty regarding whether the mutation impacts protein occupancy at 
adjacent sites. (B) Human +9.5 mutations found in patients with GATA-2 deficiency syndrome (2, 9).
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compensation for the LT-HSC reduction. These results indicate that 
WGATAR is insufficient to support developmental hematopoiesis 
without the neighboring E-box and Ets motifs.
The Gata2 +9.5 enhancer Ets motif is dispensable for HSPC 
genesis. To test models for how the human disease Ets mutation 
(1017+572C>T) impacts GATA-2 regulation and function, we gen-
erated a mouse strain harboring the disease mutation (Figure 4, A 
and B). Whereas +9.5–/– and +9.5(E-box Ets)–/– embryos exhibited 
severe anemia and hemorrhaging at E12.5 and died by E14.5 (Figure 
2F and Table 1) (2), +9.5(Ets)–/– mice lacked hemorrhages (Figure 
4C) and were born at Mendelian ratios (Table 2). The cellularity of 
WT and +9.5(Ets)–/– fetal livers was not significantly different (Fig-
ure 4D), although Gata2 expression was approximately 50% lower 
in the mutants (Figure 4E). Importantly, the lack of an Ets require-
ment for embryogenesis distinguishes the +9.5(Ets)–/– mutant 
from all other +9.5 mutants described (Figure 2 and Figure 3) (2) .
While +9.5+/– embryos are morphologically normal (2), HSC 
emergence (4), immunophenotypic and long-term–repopulating 
fetal liver HSCs, and Gata2 expression are approximately 50% 
lower than in WT mice (1, 2). To determine whether +9.5(Ets)–/– 
embryos resemble +9.5+/– embryos, we analyzed HSC emergence. 
CD31+c-Kit+ cell numbers decreased by approximately 50% 
in +9.5(Ets)–/– embryos (Figure 5, A and B). To assess whether 
this defect persisted throughout embryogenesis, we quantified 
immunophenotypic HSCs and MPPs in E15.5 fetal liver (Figure 
5, C–E). We found that the percentages of +9.5(Ets)–/– fetal liver 
HSCs and MPPs were approximately 70% and 50% lower, respec-
tively, than in WT mice. While the percentage of +9.5(Ets)+/– fetal 
liver HSCs did not differ significantly from that in WT embry-
os, the percentage of MPPs was approximately 2-fold higher in 
+9.5(Ets)+/– embryos. Thus, unlike the E-box–spacer–WGATAR 
HSC genesis in the +9.5–/– aorta-gonad-mesonephros 
(AGM) is defective, given the lack of HSC-containing clusters 
and depletion of long-term repopulating HSCs (LT-HSCs) (1). 
To determine whether the +9.5(E-box Ets)–/– mutation impacts 
the endothelial-to-hematopoietic transition, we performed 3D 
confocal analysis of embryos to quantify emerging hematopoi-
etic cells. Endothelial and hematopoietic cells express CD31, 
and hematopoietic, but not endothelial, cells, express c-Kit 
(38). While CD31+c-Kit+ clusters were abundant in E10.5 WT 
AGM, +9.5(E-box Ets)–/– embryos lacked clusters (Figure 3, A 
and  B), indicating an HSC emergence defect.
At E13.5, the +9.5–/– fetal liver is devoid of immunophenotypic 
and LT-HSCs (Lin–CD48–CD41–Sca1+Kit+Mac1+CD150+) (2). We 
found that E13.5 +9.5(E-box Ets)–/– fetal liver was depleted of immuno-
phenotypic HSCs (Figure 3, C and D). The percentage of multipotent 
progenitors (MPPs) (Lin–CD48–CD41–Sca1+Kit+Mac1+CD150–) was 
5-fold lower than in WT littermates (Figure 3E). At this stage, the 
percentage of LT-HSCs was approximately 40% lower in +9.5(E-box 
Ets)+/– embryos than in WT embryos. MPP percentages were 2-fold 
higher in +9.5(E-box Ets)+/– embryos (Figure 3E), which may reflect 
Figure 2. The +9.5 enhancer WGATAR motif is insufficient for embryogenesis. (A) Sequences of WT (+9.5+/+) and E-box Ets–mutant [+9.5(E-box Ets)–/–] 
mice. (B) Sequence of mutant mice. (C) PCR genotyping. (D) Quantification of E13.5 liver cells from +9.5(E-box Ets+/+) (n = 11), +9.5(E-box Ets)+/– (n = 30), 
and +9.5(E-box Ets)–/– (n = 6) mice. Data are from 5 experiments. (E) E13.5 fetal livers from littermate mice. (F) E13.5 littermates with anemia, hemorrhage, 
and edema. (G) Gata2 mRNA quantification of fetal liver cells from +9.5(E-box Ets)+/+ (n = 5), +9.5(E-box Ets)+/– (n = 9), and +9.5(E-box Ets)–/– (n = 4) mice. 
Data are from 3 experiments. Quantitative data are represented as box-and-whisker plots, with bounds from the 25th to 75th percentiles, the median line, 
and whiskers ranging from minimum to maximum values. *P < 0.05, by 2-tailed, unpaired Student’s t test with Benjamini-Hochberg correction.
Table 1. Genotypes of embryos from +9.5(E-box Ets) 
heterozygous matings at developmental stages and weaning
E12.5 E13.5 E14.5 E15.5 Weaning
+/+ 6 34 5 (1) 11 62
+/– 30 71 26 (1) 27 102
–/– 12 11 (13) 0 (6) 0 (9) 0
P < 1 × 10–8, by χ2 test. Numbers in parentheses indicate the number of 
dead embryos.
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insult might exacerbate such alterations and trigger phenotypic 
alterations that do not arise with either the predisposition mutation 
alone or the secondary aberration or insult alone. Alternatively, the 
predisposition mutation might be insufficient to derail molecular 
processes in the steady state, and only after a secondary aberration 
or insult would measurable molecular alterations be manifested. 
To distinguish between these mechanisms, we used RNA-Seq to 
compare transcriptomes of Lin–Sca1+c-Kit+ (LSK) cell populations 
isolated from WT and +9.5(Ets)–/– mice. After filtering out the outly-
ing genes, the data were processed with DEseq at a FDR of 0.05 and 
a fold-change minimum of 2. Strikingly, of the 53,342 transcripts 
quantitated, only 11 were differentially expressed (Figure 6B). 
composite element, which was essential for developmental hema-
topoiesis and embryogenesis, the Ets motif was dispensable, yet it 
contributed to select +9.5 functions.
Human disease GATA2–mutant mouse model: combinatorial 
impact of a predisposition mutation and myeloablative stress on patho-
genesis. Since the Ets motif was dispensable for embryogenesis, we 
tested whether the Ets motif mutation affected adult hematopoie-
sis. Peripheral WBC, RBC, and platelet numbers were comparable 
between +9.5(Ets)–/– and WT mice (Figure 6A).
In the steady state, a predisposition mutation might gener-
ate measurable but functionally “silent” molecular alterations. In 
this scenario, a secondary genetic aberration(s) or environmental 
Figure 3. The +9.5 enhancer WGATAR motif is insufficient for HSC genesis and function. (A) Whole-mount immunostaining of E10.5 dorsal aorta (DA). 
CD31+ cells are shown in magenta and c-Kit+ cells in green. Scale bars: 100 μm. (B) c-Kit+ cell quantification within the dorsal aorta from +9.5(E-box Ets)+/+ 
(n = 3), +9.5(E-box Ets)+/– (n = 4), and +9.5(E-box Ets)–/– (n = 4) mice. Data are from 2 experiments. (C) Flow cytometric analysis of E13.5 fetal liver HSCs 
(Lin−CD41−CD48−Mac1+Sca1+Kit+CD150+) and MPPs (Lin−CD41−CD48−Mac1+Sca1+Kit+CD150–). FSC, forward scatter. (D and E) HSC and MPP quantification (per-
centage of live fetal liver cells from +9.5(E-box Ets)+/+ (n = 12), +9.5(E-box Ets)+/– (n = 19), and +9.5(E-box Ets)–/– (n = 4) mice. Data are from 3 experiments. 
Quantitative data are represented as box-and-whisker plots, with bounds from the 25th to 75th percentiles, the median line, and whiskers ranging from 
minimum to maximum values. *P < 0.05, **P < 0.01, and ***P < 0.001, by 2-tailed, unpaired Student’s t test with Benjamini-Hochberg correction.
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phenotypes might reflect hypersensitivity to 5-FU–mediated cell 
death and/or defective regeneration. Using a sublethal 5-FU dose 
(150 mg/kg), RBC, WBC, and platelet regeneration was delayed in 
+9.5(Ets)–/– mice (Figure 6E).
Since the predisposition mutation had little to no impact on 
the LSK transcriptome in the steady state, we used RNA-Seq to 
globally analyze whether the mutation affects 5-FU–induced gene 
expression changes. Differential expression analysis between 
vehicle-treated WT and 5-FU–treated LSK cells detected 2974 
genes (754 upregulated, 2220 downregulated) at a FDR of 0.05 
and a minimum fold-change of 2 (Figure 6F). Of these genes, only 
423 were differentially expressed between vehicle-treated and 
5-FU–treated mutant LSK cells (Figure 6G). Thus, the predispo-
sition mutation altered the responsiveness of 85.8% of the genes 
that were 5-FU responsive in WT LSK cells. Gene Ontology anal-
ysis indicated that genes dysregulated by the Ets motif mutation 
in cluded those linked to cell-cycle regulation (e.g., G2/M check-
point) and cellular proliferation (e.g., Myc and E2F targets) 
(Table 3). The analysis detected 630 differentially expressed 
genes between vehicle-treated mutant and 5-FU–treated 
mutant LSK cells. While 423 of these were also differentially 
expressed between vehicle-treated WT and 5-FU–treated WT 
LSK cells, the remaining 32.8% were unresponsive to 5-FU 
treatment in the WT cells. The predisposition mutation cor-
rupted the LSK transcriptome in the context of hematopoietic 
injury followed by regeneration, but not in the steady state. 
These results provide strong evidence that the Ets motif muta-
tion generates a disease predisposition.
To establish how defective Gata2 induction impacts BM, we 
analyzed histological sections 9 and 11 days after 5-FU treatment 
(Figure 7A). No gross differences between untreated samples were 
apparent, consistent with the peripheral blood counts. While both 
WT and +9.5(Ets)–/– mice were hypocellular 9 days after treatment, 
we detected regeneration 11 days after treatment in WT sections 
(Figure 7, A and B). In contrast, there was still considerable hypo-
cellularity 11 days after treatment of +9.5(Ets)–/– animals, confirm-
ing the delayed regeneration in the mutants.
Thus, we determined that the predisposition mutation had little to 
no impact on the LSK cell transcriptome, consistent with a model in 
which the predisposition mutation creates a “silent” defect that is 
manifested only upon a secondary aberration or insult.
The silent nature of the predisposition mutation led us to ques-
tion what triggers the emergence of pathogenic phenotypes. We 
reasoned that an increased demand on the hematopoietic system 
involving the transition of quiescent-to-proliferating HSCs and 
HSPC regeneration might unveil deleterious phenotypes in mutants 
harboring the predisposition mutation. To test whether myeloabla-
tion-induced stress reveals Ets activity, we used 5-fluorouracil (5-FU) 
to kill cycling cells and promote HSC proliferation, thereby regener-
ating the hematopoietic system (39). Two doses of 5-FU (250 mg/
kg) were administered with an eleven-day interval for maximal stim-
ulation of HSPC expansion (40). The +9.5(Ets)–/– mice had a reduced 
median survival of 14 days versus 22 days for WT mice (Figure 6C).
During regeneration, Gata2 transcripts are induced in the 
BM LSK cell population (40). We performed quantitative reverse 
transcription PCR (qRT-PCR) of BM and RNA-Seq analysis of LSK 
cells and found that Gata2 transcript levels did not differ signifi-
cantly in BM from untreated +9.5(Ets)–/– mice compared with that 
from WT mice (Figure 6D). In contrast, 9 days after 5-FU treat-
ment, Gata2 expression increased by approximately 15-fold in BM 
from WT mice, but not in that from +9.5(Ets)–/– mice (Figure 6D). 
The Ets motif was therefore essential for myeloablation-induced 
Gata2 expression and function. In principle, the Ets motif–mutant 
Figure 4. The +9.5 enhancer Ets motif is dispensable for HSC emergence. (A) Sequences of WT [+9.5(Ets)+/+] and Ets motif-mutant [+9.5(Ets)–/–] embryos.  
Asterisk indicates C>T transition. (B) Sequences of +9.5+/+ and +9.5(Ets)–/– animals. (C) E15.5 littermates. (D) Quantification of E15.5 liver cells from +9.5+/+ 
(n = 18), +9.5(Ets)+/– (n = 20), and +9.5(Ets)–/– (n = 10) embryos. Data are from 4 experiments. (E) Gata2 mRNA quantification in fetal liver cells from 
+9.5(Ets)+/+ (n = 4), +9.5(Ets)+/– (n = 7), and +9.5(Ets)–/– (n = 5) embryos. Data are from 2 experiments. Quantitative data are represented as box-and- 
whisker plots, with bounds from the 25th to 75th percentiles, the median line, and whiskers ranging from minimum to maximum values. *P < 0.05 and 
**P < 0.01, by 2-tailed, unpaired Student’s t test with Benjamini-Hochberg correction.






P = 0.23, by χ2 test.
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To analyze +9.5(Ets)–/– BM cellularity, we quantified immuno-
phenotypic HSPCs in untreated and treated (9 and 11 days after 
5-FU) mice. In the untreated mice, we observed that +9.5(Ets)–/– 
and WT HSCs (Lin−Sca1+Kit+CD48–CD150+, common myeloid 
progenitors (CMPs) (Lin−Sca1–Kit+FcγR–CD34+), granulocyte 
macrophage progenitors (GMPs) (Lin−Sca1–Kit+FcγR+CD34+), 
and megakaryocyte-erythrocyte progenitors (MEPs) (Lin−Sca1– 
Kit+FcγR–CD34–) were unaffected (Figure 8, A and B). MPP 
(Lin–Sca1+Kit+CD48–CD150–) percentages were 9-fold lower in 
mutants (Figure 8, A and B). Nine days after 5-FU treatment, 
HSC percentages were 12-fold higher in WT animals and were 
maintained at 11 days after treatment (Figure 8, A and B). The 
disease mutation abrogated the HSC increase. While all immuno-
phenotypic progenitor cell populations were severely depleted by 
5-FU after 9 days, 11 days after 5-FU treatment, WT progenitor 
percentages were 3.6- to 5.9-fold higher than those in untreated 
animals (Figure 8, A and  B). In contrast, mutant progenitor per-
centages were restored only to the steady-state level. Thus, Ets 
confers Gata2 expression as a vital step in HSPC regeneration. To 
assess HSC function, BM from untreated animals was competi-
tively transplanted into lethally irradiated mice. Sixteen weeks 
after transplantation, we observed that the +9.5(Ets)–/– BM multi-
lineage repopulating activity was 3.0-fold lower (P < 0.0001) than 
that of WT BM (71 ± 4.6% and 23 ± 6.0% for mutant vs. WT BM, 
respectively) (Figure 9A). Analysis of donor-derived hematopoi-
etic precursors in BM reconstituted with +9.5(Ets)–/– cells revealed 
significant reductions in LSK, HSC, LS–K, CMP, GMP, and MEP 
percentages relative to those in WT donor BM (Figure 9B).
Regeneration after hematopoietic injury, such as that caused 
by 5-FU–induced myeloablation, involves increased expression 
of the HSC-regulatory genes Scl, Gata2, and Ets variant 2 (Etv2) 
(40), each of which contains binding motif(s) within the +9.5 
enhancer. ETV2 occupies the +9.5 enhancer in mouse embryonic 
stem cell–derived embryoid bodies (Figure 10A, irreproducible 
discovery rate [IDR] <0.01), and the +9.5 Ets motif mutant pheno-
copied the conditional deletion of Etv2 encoding a hematopoietic/ 
vascular-regulatory ETS factor (40, 41). While ETV2 deficiency 
does not affect progenitors or blood cells in the steady state, vas-
cular (42) or hematopoietic (40) injury induces ETV2, which then 
functions to promote recovery. Given the hundreds of ETV2 chro-
matin occupancy sites detected by ChIP-Seq, it is striking that the 
single-nucleotide mutation in the +9.5 enhancer disrupts hema-
topoietic regeneration in a manner analogous to the conditional 
deletion of ETV2 throughout the hematopoietic system. To test 
Figure 5. The +9.5 enhancer 
Ets motif is dispensable for 
HSC emergence. (A) Whole-
mount immunostaining of 
E10.5 dorsal aorta. CD31+ cells 
are shown in magenta and 
c-Kit+ cells in green. Scale 
bars: 100 μm. (B) c-Kit+ cell 
quantification within the 
dorsal aorta from +9.5+/+  
(n = 6), +9.5(Ets)+/– (n = 8), 
and +9.5(Ets)–/– (n = 6) mice. 
Data are from 4 experiments. 
(C) Flow cytometric analy-
sis of E15.5 fetal liver HSCs 
(Lin−CD41−CD48−Mac1+S-
ca1+Kit+CD150+) and MPPs 
(Lin−CD41−CD48−Mac1+S-
ca1+Kit+CD150–). (D and E) 
Quantification of HSCs and 
MPPs (percentage of live fetal 
liver cells) from +9.5(Ets)+/+  
(n = 9), +9.5(Ets)+/– (n = 11), and 
+9.5(Ets)–/– (n = 8) mice. Data 
are from 2 experiments. Quan-
titative data are represented 
as box-and-whisker plots, 
with bounds from the 25th to 
75th percentiles, the median 
line, and whiskers ranging 
from minimum to maximum 
values; *P < 0.05, **P < 0.01, 
and ***P < 0.001, by 2-tailed, 
unpaired Student’s t test 
with Benjamini-Hochberg 
correction.
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whether there is a hierarchical relationship between ETV2 and 
Gata2 in the hematopoietic injury response, we quantified Gata2 
expression in regenerating HSPCs from WT and Tie2-Cre Etv2fl/fl 
conditional–knockout mice after 5-FU injury. We found that Gata2 
expression was 1.5-fold lower (P = 0.001) in Etv2fl/fl LSK cells than 
in WT cells after 5-FU treatment (Figure 10B), suggesting that 
ETV2 functions upstream of GATA-2 in the injury response.
Discussion
Recurring GATA2 mutations in human pathologies (11, 14, 43) high-
light vital GATA-2 functions (18, 32, 44), some of which were predict-
able on the basis of prior studies of Gata2-mutant mouse models. As 
decreased (2, 6, 9) or elevated GATA-2 (45, 46) levels disrupt hema-
topoiesis, establishing and maintaining GATA-2 expression within a 
physiological window is crucial. Though this control is accomplished, 
in part, via +9.5 and –77 enhancer–dependent transcriptional induc-
tion of GATA-2 expression, many questions remain unanswered 
regarding the underlying mechanisms, including the relative contri-
butions (qualitative and quantitative) of the individual cis-elements 
constituting the enhancers to enhancer function in diverse develop-
mental and adult contexts, as well as the constitution of regulatory 
factors conferring or suppressing enhancer activity.
Mechanistic and pathological insights have emerged from 
analyses of Gata2 mouse models, including Gata2 enhancer 
Figure 6. The +9.5 enhancer Ets motif confers hematopoietic regeneration and survival following stress. (A) Steady-state peripheral blood parameters 
(n = 18 per genotype). (B) MA plot summarizing RNA-Seq analysis of transcripts from BM-derived WT and +9.5(Ets)–/– LSK cells in the steady state. (C) 
Kaplan-Meier survival curve for mice following two 5-FU doses (250 mg/kg, days 0 and 11): +9.5+/+ (n = 17), +9.5(Ets)+/– (n = 23), and +9.5(Ets)–/– (n = 10). 
Data are from 2 experiments. Significance was determined using the log-rank test. (D) qRT-PCR quantitation of mRNA from BM 9 days after vehicle (PBS) 
or 5-FU (250 mg/kg) treatment of +9.5+/+ (n = 8) and +9.5(Ets)–/– (n = 8) mice. Data are from 4 experiments. Quantitative data are represented as box-and-
whisker plots, with bounds from the 25th to 75th percentiles, the median line, and whiskers ranging from minimum to maximum values. **P < 0.01, by 
Tukey’s multiple comparisons test. (E) Hematologic parameters following 5-FU treatment (150 mg/kg). n = 9 per genotype; data are from 3 experiments. 
(F) MA plot summarizing RNA-Seq analysis of transcripts from BM-derived WT and +9.5(Ets)–/– LSK cells on day 10 after treatment with 5-FU. (G) Rela-
tionships derived from the RNA-Seq data in F. Venn diagram compares 5-FU–regulated (total upregulated and downregulated) transcripts in BM-derived 
WT and +9.5(Ets)–/– LSK cells on day 10 after 5-FU treatment. These relationships were further deconvoluted by separating 5-FU–upregulated transcripts 
from the downregulated transcripts. PLTs, platelets.
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confer the critical +9.5 enhancer activity and the control of devel-
opmental hematopoiesis (Figure 11). While the Ets motif was dis-
pensable in embryos and adults in the steady state, the Ets motif 
disease mutation abrogated myeloablation-dependent GATA-2 
induction and hematopoietic regeneration in BM. Myeloablation 
increased GATA-2 expression and HSC numbers in the BM of WT, 
but not +9.5(Ets)–/–, mice. Combined with our comparison of WT 
and +9.5(Ets)–/– LSK cell transcriptomes, these results establish a 
pathogenesis paradigm, in which the Ets motif disease mutation 
is, in effect, “silent” and singularly does not corrupt the LSK tran-
scriptome or steady-state hematopoiesis. Because the mutation 
altered the capacity of 5-FU to induce transcriptomic changes, the 
mutation predisposed the cells to a secondary insult that instigat-
ed hematopoietic failure.
It is instructive to consider what qualitative insults and quan-
titative changes initiate and/or accelerate pathogenesis. While 
we used mild or severe myeloablation, does a damage threshold 
constitute a binary switch to trigger pathogenesis, or does mod-
est stress induce phenotypes that are reversible or compensated 
mutants with impaired HSPC levels and functions (1, 2, 4, 5, 21, 
23, 24). Here we dissected models governing +9.5 enhancer func-
tion and discovered that the WGATAR motif, without E-box and 
Ets motifs, was insufficient for embryogenesis and developmen-
tal hematopoiesis; WGATAR required additional cis-elements to 
Table 3. Gene Ontology (Database for Annotation, Visualization, 








P values were determined by Fisher’s exact test.
Figure 7. The +9.5 enhancer Ets motif promotes hematopoietic regeneration after stress. 
(A) H&E staining of BM after treatment with vehicle (PBS) or 9 or 11 days after treatment 
with 5-FU (250 mg/kg). Scale bars: 50 μm. (B) Quantification of BM cells as shown in A. n = 4 
per genotype and condition; data are from 4 experiments. Quantitative data are represented 
as box-and-whisker plots, with bounds from the 25th to 75th percentiles, the median line, 
and whiskers ranging from minimum to maximum values. *P < 0.05, by 2-tailed, unpaired 
Student’s t test with Benjamini-Hochberg correction.
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Figure 8. +9.5 enhancer Ets motif–dependent HSPC regeneration. BM was harvested 9 or 11 days after vehicle (PBS) or 5-FU (250 mg/kg) treatment. (A) Flow 
cytometric analysis of LSK cells (Lin−CD48−Sca1+Kit+), HSCs (Lin−CD48−Sca1+Kit+CD150+), MPPs (Lin−CD48−Sca1+Kit+CD150–), LS–K cells (Lin−Sca1–Kit+), MEPs 
(Lin−Sca1–Kit+FcγR–CD34–), CMPs (Lin−Sca1–Kit+FcγR–CD34+), and GMPs (Lin−Sca1–Kit+FcγR+CD34+). (B) LSK, HSC, MPP, LS–K, MEP, CMP, and GMP quantification 
(percentage of live BM cells). n = 8–10 per genotype and treatment; data are from 5 experiments. Quantitative data are represented as box-and-whisker plots, 
with bounds from the 25th to 75th percentiles, the median line, and whiskers ranging from minimum to maximum values. *P < 0.05, **P < 0.01, and ***P < 
0.001, by Tukey’s multiple comparisons test.
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G A C T G A G T C G A G G T G G C T C T G A A A A C T T G C C G G T C -
CAGAAACAGATACACGAAGTTTCCTTATCTACCGGCTGCAGAT-
GTCCGGATAGGAAACTCCGGC-3′) The C>T transition, without 
additional mutations, was detected in 4 of 25 live pups by DNA sequenc-
ing at and surrounding the mutation site. One additional founder con-
tained the Ets point mutation and a 28-bp deletion corrupting the E-box 
motif. Further genotyping was performed using a TaqMan Assay (ABI, 
6253771_1) or the primers Gata2 –78 forward: CACACAGCGGCCAC-
CAA and Gata2 +120 reverse: AAAGCGGGTGAACGATTTAAAC.
Mouse embryo isolation. Embryos were obtained from timed matings 
between heterozygous males and females, with the day of vaginal plug 
detection considered day 0.5. Pregnant females were euthanized with 
CO2, and fresh embryos were transferred into ice-cold PBS for dissection.
qRT-PCR. Total RNA was purified with TRIzol (Invitrogen, Thermo 
Fisher Scientific). DNAse (Invitrogen, Thermo Fisher Scientific) treat-
ment was performed on 0.1 to 1 μg RNA at 25°C for 15 minutes, followed 
by addition of 2.5 mM EDTA at 65°C for 10 minutes. cDNA was prepared 
by annealing with 250 ng of a 1:5 mixture of random hexamer and oligo-
nucleotide (dT) primers incubated with m-MLV Reverse Transcriptase 
(Invitrogen, Thermo Fisher Scientific) with 10 mM DTT, RNasin (Prome-
ga), and 0.5 mM dNTPs at 42°C for 1 hour, followed by heat inactivation 
at 95°C for 5 minutes. cDNA was analyzed in reactions (20 μl) containing 
2 μl cDNA, primers, and 10 μl Power SYBR Green (Applied Biosystems) 
by qRT-PCR with a Viia7 Real-Time RT-PCR Cycler (Applied Biosyste-
ms). Standard curves of serial 1:5 dilutions of cDNAs were prepared from 
control cDNA with the highest predicted gene expression. Values were 
normalized to the standard curve and 18S control.
Whole-embryo confocal microscopy. E10.5 embryos were fixed, 
stained, and analyzed as described previously (1, 38). Embryos were 
stained with biotinylated anti–PECAM-1 (BD Biosciences, 553371) and 
anti–c-Kit (BD Biosciences, 553352) antibodies. Samples were mounted 
in a 1:2 mixture of benzyl alcohol (Sigma-Aldrich, 402834) and benzyl 
benzoate (Acros Organics, 105862500) to increase tissue transparency 
and then visualized with a Nikon A1RS Confocal Microscope. 3D 
reconstructions were generated from Z-stacks (80–200 optical sec-
tions) using Fiji software.
for? Our model will enable this problem to be rigorously dissected 
in the contexts of environmental insults and genetic aberrations. 
As mimicking viral infection with the type I IFN inducer polyinos-
inic:polycytidylic acid (pI:pC) in Fanca–/– mice resulted in HSC 
functional defects (47), high levels of DNA damage, and BM fail-
ure, there may be mechanistic parallels between this system and 
the defective hematopoietic regeneration caused by the Gata2 Ets 
motif predisposition mutation.
We provide evidence for a new mechanism in human genet-
ics, in which a disease mutation of a cis-element inactivates the 
regenerative activity of an enhancer, while sparing its develop-
mental activities, which require multiple cis-elements. Dissecting 
this mechanism in the unique mouse model described here estab-
lished a paradigm in which the cis-element predisposition muta-
tion, combined with a secondary insult, corrupts hematopoietic- 
regulatory mechanisms, leading to hematopoietic failure, a feature 
of GATA-2-deficiency syndrome in humans. Furthermore, these 
studies illustrate the power of microdissecting enhancers to unveil 
physiological and pathological mechanisms.
Methods
Statistics. Results are presented as either the mean ± SEM or as box-and-
whisker plots, with bounds from the 25th to the 75th percentiles, the 
median line, and whiskers ranging from minimum to maximum values. 
Multiple independent cohorts were used in each experiment. Statisti-
cal comparisons were performed using 2-tailed Students t tests (signif-
icance cutoff of P < 0.05) , with correction of statistical overrepresen-
tation of functions calculated using the Benjamini-Hochberg multiple 
tests correction procedure or Tukey’s multiple comparisons test. A log-
rank test was performed on the Kaplan-Meier survival curve. GraphPad 
Prism (GraphPad Software) was used to perform the statistical analyses.
Generation of mutant mice. Pronuclear injection was conducted on 
a C57BL/6J background at the 1-cell zygote stage at the UW-Madison 
Biotechnology Center using recombinant Cas9, guide RNA 
(gRNA) (5′-TCGTGTATCTGTTTCCGGACCGG-3′), and repair 
oligo nucleotide (5′-TTTCAAAACAGCCCAGCAAGAGGCAG-
Figure 9. +9.5 enhancer Ets motif–dependent regeneration of LT-HSCs. (A) Multilineage repopulating activity 16 weeks after competitive transplanta-
tion (n = 10 per genotype). *P < 0.05 and ***P < 0.001, by 2-tailed, unpaired Student’s t test. (B) Analysis of donor-derived LSK cells, HSCs, MPPs, LS–K 
cells, CMPs, GMPs, and MEPs in BM 16 weeks after competitive transplantation (n = 10 per genotype). Statistical significance was determined by 2-tailed, 
unpaired Student’s t test.
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Histological analysis. Femurs were fixed with 10% neutral-buffered 
formalin (Dot Scientific, DSF10800-500) and embedded in paraffin 
using standard procedures. Sections (10-μm) were stained with H&E. 
The hematopoietic content of serial images along the entire length of 
the femurs was quantified.
Flow cytometric analysis. Fetal liver or BM was dissociated and 
resuspended in IMDM with 2% FBS and passed through 25-μm cell 
strainers to obtain single-cell suspensions prior to antibody staining. 
All antibodies were purchased from eBioscience (Thermo Fisher Sci-
entific) unless otherwise stated. Lineage markers for the LSK cell pop-
ulations were stained with the FITC-conjugated antibodies B220 (11-
0452), CD3 (11-0031), CD4 (11-0041), CD5 (11-0051), CD8 (11-0081), 
CD41 (11-0411) (for fetal liver only), CD48 (11-0481), Gr-1 (11-5931), 
and TER-119 (11-5921). Other surface proteins were detected with 
PE-conjugated CD150 (BioLegend, 115904; PE-Cy7–conjugated Mac1, 
25-0112 [for fetal liver only]); PerCP-Cy5.5–conjugated Sca1, and 
allophycocyanin-conjugated (APC-conjugated) c-Kit (2B8, 17-1171) anti-
bodies. Analysis of myeloid progenitors was conducted as described in 
Johnson et al. (5). Lineage markers were stained with FITC-conjugated 
B220, CD3, CD4, CD5, CD8, CD19 (11-0193), IgM (11-5890), Il7Ra 
(11-1271), AA4.1 (11-5892), and TER-119 antibodies. Other surface pro-
teins were detected with PE-conjugated FcγR (12-0161), eFluor 660– 
conjugated CD34 (50-0341), PerCP-Cy5.5–conjugated Sca1 (45-5981), 
and PE-Cy7–conjugated c-Kit (BioLegend, 105814). After staining, 
cells were washed with PBS and resuspended in IMDM, 2% FBS, and 
DAPI and analyzed on a LSR II Flow Cytometer (BD Biosciences).
RNA-Seq. BM from 5-FU– or PBS-treated animals (10 days after 
treatment) was dissociated, resuspended in IMDM with 10% FBS and 
passed through 25-μm cell strainers to obtain single-cell suspensions 
prior to antibody staining. LSK cells (B220–CD3–CD4–CD5–CD8–Sca1+ 
c-Kit+; 3,000–10,000 cells per replicate) were collected on a FACSAria 
II cell sorter (BD Biosciences). RNA was purified using an RNAeasy 
Micro Kit (QIAGEN, 74004). RNA libraries were prepared for sequenc-
5-FU myeloablation model. Myeloablation was induced by a single 
dose (150 mg/kg) or 2 doses (250 mg/kg) of 5-FU (MilliporeSigma, 
F6627) administered intraperitoneally on days 0 and 11. Blood sam-
ples were collected by retro-orbital bleeding (~10 μl per collection), 
and hematologic parameters were quantified on a HemaVet complete 
blood count (CBC) instrument (Drew Scientific).
BM isolation. BM from femurs and tibiae of 8- to 14-week-old 
mice was collected by removing epiphyses and flushing the BM with a 
25-gauge needle and syringe containing IMDM plus 2% FBS.
Figure 10. Evidence for an ETV2/GATA-2 regenerative axis. (A) ETV2 
ChIP-Seq. ETV2 occupancy was detected at the +9.5 enhancer in mouse 
embryonic stem cell–derived embryoid bodies (GEO GSE59402) (41). (B) 
Sorted LSK cells from WT (n = 6) or Tie2-Cre Etv2 conditional–knockout 
mice (n = 6) 10 days after 5-FU injection (250 mg/kg). Gata2 mRNA levels 
were normalized to Actb. **P < 0.01, by 2-tailed, unpaired Student’s t test.
Figure 11. Human disease predisposition mutation segregates developmental versus regenerative enhancer functions. Model depicts the +9.5(E-box 
Ets)–/– HSC emergence and fetal liver hematopoietic defects, which phenocopy the previously described +9.5–/– phenotype. Both mutations are embryon-
ically lethal. In contrast, the human disease +9.5 Ets motif mutant is not an embryonically lethal mutation. In adult mice, the mutation impedes HSPC 
regeneration. We propose that the human mutation renders the hematopoietic system vulnerable to subsequent insults that demand HSPC regeneration 
to reestablish the steady state. The intimate connection between the predisposition mutation and mechanisms elicited by secondary insults may underlie 
the variable penetrance of disease onset in GATA-2 deficiency syndrome.
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